Lineage Cell Q4 revenue rises on Genentech collaboration

Lineage Cell Therapeutics

05/03/2026 21:11

Overview

Biotechnology firm's Q4 revenue rises, driven by collaboration with Genentech and Roche

Company reports net income for Q4, reversing loss from previous year

Company enters collaboration with William Demant Invest for hearing loss therapy

Outlook

Lineage expects cash to support operations into Q2 2028

Company plans to advance therapeutic candidates in 2026

Lineage aims to achieve key clinical and financial milestones in 2026

Result Drivers

COLLABORATION REVENUE - Revenue increase driven by collaboration with Roche and Genentech following milestone achievement

ALLOSCOPE PLATFORM - Demonstrated high-scale production potential of AlloSCOPE manufacturing platform

OPREGEN ADVANCEMENTS - Achieved first milestone in collaboration with Roche and Genentech, reflecting manufacturing and clinical progress

Company press release: ID:nBw8v4M7ra

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$63.37 mln
FY Income from Operations
-$36.62 mln
FY Operating Expenses
$51.18 mln
FY Pretax Profit
-$68.65 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Lineage Cell Therapeutics Inc is $3.00, about 54.2% above its March 4 closing price of $1.95

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)